GSA Capital Partners LLP Makes New $1.18 Million Investment in MoonLake Immunotherapeutics $MLTX

GSA Capital Partners LLP purchased a new position in MoonLake Immunotherapeutics (NASDAQ:MLTX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 89,236 shares of the company’s stock, valued at approximately $1,176,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MLTX. FNY Investment Advisers LLC bought a new position in MoonLake Immunotherapeutics in the third quarter worth approximately $28,000. Bank of America Corp DE boosted its holdings in MoonLake Immunotherapeutics by 64.7% in the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after acquiring an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of MoonLake Immunotherapeutics by 115.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after purchasing an additional 3,166 shares in the last quarter. Covestor Ltd bought a new position in shares of MoonLake Immunotherapeutics in the third quarter valued at approximately $46,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of MoonLake Immunotherapeutics by 18.9% in the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock valued at $52,000 after purchasing an additional 1,158 shares in the last quarter. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Stock Up 8.3%

MLTX stock opened at $18.47 on Friday. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The company has a quick ratio of 8.60, a current ratio of 8.60 and a debt-to-equity ratio of 0.39. The stock’s 50 day moving average is $17.41 and its 200-day moving average is $15.76. The firm has a market capitalization of $1.32 billion, a PE ratio of -4.77 and a beta of 1.01.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.07). Sell-side analysts expect that MoonLake Immunotherapeutics will post -3.71 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Bvf Partners L. P/Il sold 3,750,000 shares of the stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $16.79, for a total transaction of $62,962,500.00. Following the completion of the sale, the director directly owned 1,039,238 shares of the company’s stock, valued at approximately $17,448,806.02. This trade represents a 78.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Da Silva Jorge Santos sold 51,873 shares of the stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $18.23, for a total value of $945,644.79. Following the sale, the chief executive officer directly owned 2,924,893 shares of the company’s stock, valued at $53,320,799.39. The trade was a 1.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,900,000 shares of company stock valued at $65,714,663 over the last ninety days. 12.02% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

MLTX has been the topic of a number of recent research reports. Zacks Research upgraded MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Oppenheimer raised their target price on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Tuesday, February 24th. Royal Bank Of Canada raised their target price on MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the company a “sector perform” rating in a report on Monday, March 2nd. Needham & Company LLC raised their target price on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 12th. Nine research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics currently has an average rating of “Hold” and a consensus price target of $23.85.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.